Eli Lilly and Company Stock News

Is It Time to Sell Eli Lilly and Pfizer Stocks?

— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics' AI-Enabled, All-in-Human CONVERGE® Platform

INDIANAPOLIS , Nov. 19, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors, effective Dec. 1, 2024. In addition, the company announced that Karen Walker will transition her role with Lilly, resigning as a member of Lilly's board of directors effective Dec. 31, 2024.

Eli Lilly's cholesterol pill impressed in a mid-stage trial. Meanwhile, Dexcom invested $75 million in Oura.

Der Insulin-Weltmarktführer Novo Nordisk konnte zuletzt vor allem mit dem Abnehmmittel Wegovy überzeugen. In Zukunft sollen weitere Gewinnbringer her.

The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in a mid-stage trial, according to data presented at a medical meeting on Monday.

Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 study These data were published in the Journal of the American Medical Association (JAMA) and simultaneously presented today at the American Heart Association (AHA) Scientific Sessions 2024 INDIANAPOLIS , Nov. 18, 2024 /PRNewswire/ -- Eli Lilly a...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an analysis shared with Reuters.